




REFERENCES

- Antoniadou H.N.; Gundersen K.; and Beigelman P.M.:
Studies on the state, transport, and regulation of insulin in human blood.
Diabetes, 11: 261-6, 1962.
- Anderson J.: Clinical and metabolic study in diabetic patients treated with
Glibenclamide. *Br.Med.J.*, 2: 568-74, 1970.
- Ashcroft S.J.H.; Bassett J.M.; and Randle P.J.: Insulin secretion mechanisms and
glucose metabolism in isolated islets. *Diabetes*, 21 (Suppl.2): 538-46, 1972.
- Ahuja M.M.S.; Gupta S.P.; and Sehgal N.K.: Efficacy of glibenclamide in
maturity-onset diabetics as maintenance therapy. *Horm.Metab.Res.*, 5: 160-5,
1973.
- Almer L.O.; and Nilsson I.M.: On fibrinolysis in diabetes mellitus. *Acta*
Med.Scand., 198: 101-111, 1975.
- Archer J.A.; Gorden P.; and Roth J.: Defect in insulin binding to receptors in
obese man: Amelioration with calory restriction. *J.Clin.Invest.*, 55: 166-73, 1975.
- Almer L.O.; and Pandolfi M.: Fibrinolysis and diabetic retinopathy.
Diabetes, 25 (Suppl.2): 807-15, 1976.
- Abraham E.C.; Huff T.A.; and Cope N.D.: Determination of the glycosylated
hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the
technique for assessing the clinical management of diabetes mellitus. *Diabetes*,
27(9): 931-7, 1978.
- Al-Sayegh H.; and Jarrett R.J.: Oral glucose tolerance test and the diagnosis of
diabetes results of a prospective study based on the Whitehall Survey. *Lancet*, 2:
431-8, 1979.
- Archer J.A.: Insulin receptors on erythrocytes: influence of oral antidiabetic
agents. Upjohn Monograph # 8875. *Lancet*, 1: 77-85, 1979.
- Aiello L.M.; Rand L.T.; and Briones J.C.: diabetic retinopathy in Joslin Clinic
patients with adult-onset diabetes mellitus. *Ophthalmology*, 88: 619-23, 1981.
- Ashby J.; and Frier B.: Circulating C-peptide: Measurement and Clinical
Application. *Annual Of Clinical Biochemistry*, 18: 125-30, 1981.
- Atkinson Mark A.; and Maclaren k.: 64,000 Mr autoantibodies as predictors
of insulin-dependent diabetes mellitus. *Lancet*, 335: 1357-1360, 1990.

- Ardehali A.; Laks H.; and Drinkwater D.C.: Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. *Circulation*, 92(3): 450-6, 1995.
- Aanstoot H.J.; Kang S.M.; Kim J.; Lindsay L.A.; Roll U.; Knip M.; and Atkinson M.: Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type I diabetes. *J.Clin.Invest.*, 97 (12): 2772-83, 1996.
- American Diabetes Association (ADA) 1996: Position statement: Urine glucose and ketone determinations. *Diabetes care*, 19 (Suppl.1: 535-37), 1996.
- American Diabetes Association (ADA) 1997: Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes care*, 20:1183-91, 1997.
- Albertini J.P.; Valensi P.; Lormeau B.; Aurousseau M.H.; and Ferriere F.: Elevated concentrations of soluble E-Selectin and Vascular Cell Adhesion Molecule-1 (VCAM-1) in NIDDM. Effect of intensive insulin treatment. *Diabetes Care*, 21 (6): 1008-13, 1998.
- American Diabetes Association (ADA): Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*, 23(1) suppl.S4-S9, 2000.
- Bertram F.: Zum Wirkungsmechanismus des Synthalins. *Dtsch.Arch-Eklin-Med.*, 158: 76-81, 1927.
- Bertram F.: Die Behandlung des Diabetes Mellitus mit Kleinen Dosen von Guanidin derivaten. *Med.Klin.*, 24: 1229-34, 1928.
- Bertram F.; Benfeldt E; and Otto H.: Uber ein wirksames perorales Antidiabeticum (Bz-ss) *Dtsch.Med.Wochenschr.*, 80: 1945-48, 1955.
- Best C.H.: The first clinical use of insulin. *Diabetes J.*, 65-70, 1956.
- Berson S.A.; and Yallow R.S.: Insulin Antagonists, insulin antibodies, and insulin resistant. *Am.J.Med.*, 25: 155-161, 1958.
- Bander A.: The mode of hyperglycemic action of sulfonylureas D 860 and Bz 55. *German Med. Monthly*, 4: 373-379, 1959.
- Blaschko H.; Firemark H.; Smith A.D.; and Winkler H.: Lipids of the adrenal medulla. Lysolecithin, a characteristic constituent of chromaffin granules. *Biomedica.J.*, 104: 545-53, 1967.
- Banerjee R.N.; Sahni A.L.; Kumar V.; and Arya M.: Antithrombin III deficiency

in maturity onset diabetes mellitus and atherosclerosis.
 Thromb.Diath.Haemorrh., 31: 339-42, 1974.

- Barnes A.J.; Crowley M.F.; Garbien K.J.T; and Bloom A.: Effect of short and long term chlorpropamide treatment in insulin release and blood glucose Lancet, 1: 69-72, 1974.
- Bottazzo G.F.; Florin-Christensen A.; and Doniach D.: Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, 2: 1279-83, 1974.
- Blobel G.; and Dobberstein R.: Transfer of proteins across membranes. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane bound ribosomes of murine myeloma. J.Cell.Biol., 67: 835-41, 1975.
- Bunn H.F.; Haney D.N.; Gabbay K.H.; and Gallop P.M.: Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c Biochem.Biophys.Res.Comm., 67: 103-6, 1975.
- Botazzo G.R.; Doniach D.; and Pouplard A.: Humoral autoimmunity in diabetes Mellitus. Acta Endocrinol., 83 (suppl.205): 55-63, 1976.
- Barnes A.J.; Locke P.; and Scudder P.R.: Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet, 2: 789-92, 1977.
- Bunn H.F.; Gabbay K.H.; and Gallop P.M.: The glycosylation of hemoglobin: relevance to diabetes mellitus. Science, 200: 21-25, 1978.
- Buschard K.; Madspad S.; and Rygaard J.: Passive transfer of diabetes mellitus from man to mouse. Lancet, 1: 908-11, 1978.
- Bar R.S.; Harrison L.C.; and Muggea M.: Regulation of insulin receptors in normal and abnormal physiology in man. Adv.Intern.Med., 24: 23-31, 1979.
- Beck-Nielsen H.; Pedersen O.; and Lindskov H.O.: Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol., 90: 451-55, 1979.
- Beyer J.; Krause U.; and Cordes U.: C-peptide: Its biogenesis, structure, determination of clinical significance. Giornale.Ital.Chem.Clin., 4 suppl.1: 9-22, 1979.
- Bunn H.F.; Shapiro R.; and McManus M.: Structural heterogeneity of human hemoglobin A, due to non-enzymatic glycosylation. J.Biol.Chem., 254: 3892-98, 1979.
- Berger M.; Cuppers H.J.; Halban P.A.; and Offord R.E: The effect of aprotinin on

the absorption of subcutaneously injected regular insulin in normal subjects. *Diabetes*, 29: 81-86, 1980.

- Bottazzo G.F.; Dean B.M.; and Gorsuch A.N.: Complement-fixing islet cell antibodies in type I diabetes: Possible monitors of active beta-cell damage. *Lancet*, 1: 668-74, 1980.
- Blonde C.V.; Webber L.S.; Foster T.A.; and Berenson G.S.: Parental history and cardiovascular disease risk factors variables in children. *Prevent. Med.*, 10: 25-29, 1981.
- Brnett A.H.; Eff C.; Leslie R.D.G.; and Pyke D.A.: Diabetes in identical twins-a study of zoo pairs. *Diabetologia*, 20: 87-90, 1981.
- Bunn H.F.: Evaluation of glycosylated hemoglobin in diabetic patients. *Diabetes*, 30: 613-17, 1981.
- Baekkeskov S.; Nielson J.H.; and Marner B.: Autoantibodies in newly diagnostic diabetic children immunoprecipitate human pancreatic islet cell proteins. *Nature*, 298: 167-69, 1982.
- Blix P.; Boddie-Wills C.; Landau R.; Rochman H.; and Rubenstein A.: Urinary C-peptide: An indicator of Beta cell secretion under metabolic different conditions. *Journal of Clinical Endocrinology and Metabolism*, 54: 574-78, 1982.
- Bright G.M.; Blizzard R.M.; and Kaiser D.L.: Organ-specific antibodies in children with common endocrine diseases. *J. Pediatr.*, 100: 8-14, 1982.
- Burrows G.N.; Hazlett B.E.; and Phillips M.J.: A case of diabetes mellitus: Insulin, sixty years of use. *Ibid.* p. 362 (Marliss, E.B.). *N. Engl. J. Med.*, 306: 340-43, 1982.
- Beischer W.: Proinsulin and C-peptide. *Hormones in Normal and Abnormal Human Tissues*. Walter De Gruyter (In: Fotherby K.; Pal S. editors. Vol.3. Berlin) 1: 43-47, 1983.
- Buysschaert M.; Marchand E.; Ketelsleyer J.M.; and Lambart A.E.: Comparison of plasma glucose and plasma free insulin during CS II and intensified conventional insulin therapy. *Diabet. Care*, 6: 1-11, 1983.
- Bonger A.; and Garcia-Webb P.: C-peptide measurement: Methods and clinical utility. (CRC) *Crit. Rev. Clin. Lab. Sci.*, 19: 297-352, 1984.
- Brownlee M.; Valssara H.; and Cerami A.: Non-enzymatic glycosylation and the pathogenesis of diabetic complications. *Ann. Intern. Med.*, 2: 34-39, 1984.
- Bottazzo G.F.; Pujol-Parrell R.; and Gole E.: (Alberti K.G.M.M.; and Krall L.P., eds.), Elsevier N.Y. (In: *The diabetes Annual*): Oxford, 1: 16-52, 1985.

- Boitard C.; Bonifacio E.; Bottazzo G.F.; Gleichman H.; and Molenaar J.: Immunology and diabetes workshop: Report on the third international (stage 3) workshop on standardization of cytoplasmic islet cell antibodies. *Diabetologia*, 31: 451-54, 1988.
- Baekkeskov S.; Aunstoot H.J.; and Chistagau A.: Identification of the 64 K autoantigen in insulin-dependent diabetics as the GABA-Synthesizing enzyme glutamic acid decarboxylase. *Nature*, 347: 151-56, 1990.
- Bochner B.S.; Luscinskas F.W.; and Gimbrone M.A.: Adhesion of human basophils, eosinophils, and neutrophils to interleukin-1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. *J.Exp.Med.*, 173(6): 1553-7, 1991.
- Birdsall H.H.; Lane C.; and Ramser M.N.: Induction of VCAM-1 and ICAM-1 on human neural cells and mechanisms of mononuclear leukocyte adherence. *J.Immunol.*, 148 (9): 2717-23, 1992.
- Bu D.F.; Erlander M.G.; Hitz B.C.; and Tillakaratne E.: Two human glutamic decarboxylases, as 65 Kda GAD and 67-Kda GAD, are encoded by a single gene. *Proc.Natl.Acad.Sci. (USA)*, 89: 2115-19, 1992.
- Baumgartner-Parzer S.M.; Wagner L.; Pettermann M.; Gessl A.; and waldhausl W.: Modulation by high glucose level of adhesion molecule expression in cultured endothelial cells. *Diabetologia*, 38 (11): 1367-70, 1995.
- Beischer N.A.; Wein P.; Sheedy M.T.; Mackay I.R.; and Rowley M.J.; and Zimmer P.: Prevalence of antibodies to glutamic acid decarboxylase in women who have had gestational diabetes. *Am.J.Obestet.Gynecol.*, 173 (s): 1563-9, 1995
- Brownlee M.: Advanced protein glycosylation in diabetes and aging. *Annu.Rev.Med.*, 46: 223-34, 1995.
- Bannen S.; Mansfield M.W.; and Grant P.J.: Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in IDDM patients. *Diabetologia*, 41 (4): 460-6, 1998 (Apr.).
- Bonifacio E.; Lampasona V.; and Bingley P.J.: IA-2 (Islet cell antigen 512) is the primary target of humoral autoimmunity against type I diabetes-associated tyrosine phosphate autoantigens. *J.Immunol.*, 161 (S): 2648-54, 1998 (Sep.).
- Brooks-Worrell B.M.; Juneia R.; Minokadeh A.; Greenbaum C.J.; and Palmer J.P.: Cellular immune responses to human islet proteins in antibody-positive (type 2) diabetic patients. *Diabetes*, 48 (5): 983-8, 1999 (May).
- Berger B.; Stenstrom G.; and Sundkvist G.: Random C-peptide in the classification of diabetes. *Scand-J-Clin-Lab-Invest.*, 60 (8): 687-93, 2000.

- Betterle C.; Fusari A.; and Presotto F.: Pancreatic autoantibodies in Italian patients with newly diagnosed type 1 diabetes mellitus under the age of 20 years. *Ann-N-Y-Acad-Sci.*, 958: 271-5, 2002.
- Bluher M.; Unger R.; and Rassoul F.: Relation between glycemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose intolerance or type 2 diabetes. *Diabetologia*, 45 (2): 210-6, 2002.
- Conn J.W.; and Fajans J.J.: The prediabetic State. *Am.J.Med.*, 31: 839-42, 1961.
- Cerasi E.; and Luft R.: Diabetes Mellitus. A disorder of cellular transmission? *Horm.Metab.Res.*, 2: 246-52, 1970.
- Cahil G.F.: Physiology of insulin in man. *Diabetes*, 20: 785-98, 1971.
- Cerasi E.: Mechanisms of glucose stimulated insulin secretion in health and in diabetes: Some re-evaluation and proposals. *Diabetologia*, II: 1-8, 1975.
- Cahil G.F.; Etzwiler D.D.; and Freinkel N.: Blood glucose control in diabetes. *Diabetes*, 25: 237-43, 1976.
- Cahil G.F.; Etzwiler D.D.; and Freinkel N.: "Control" and diabetes. *N.Engl.J.Med.*, 294: 1004-9, 1976.
- Chan S.J.; Keim P.; and Steiner D.F.: Cell-free synthesis of rat proinsulin: Characterization and partial amino acid sequence determination. *Proc.Natl.Acad.Sci.(USA)*, 73: 1964-69, 1976.
- Christy M.; Deckert T.; and Nerup J.: Immunity and autoimmunity in diabetes mellitus. *Clin.Endocrinol.Metab.*, 6: 305-17, 1977.
- Crofford O.: Diabetes Data. DHEW Pub.No. (NIH) 78-1468. Bethesda, National Diabetes Data Group pp.: 8-11, 1977.
- Craighead J.E.: Current view on the etiology of insulin dependent diabetes mellitus. *N.Engl.J.Med.*, 299: 1439-56, 1978.
- Cunha-Vaz J.G.; Fonseca J.R.; de Abreu J.R.F.; and Lima J.J.: Studies on retinal blood flow. II.Diabetic Retinopathy. *Arch.Ophthalmol.*, 96: 809-15, 1978.
- Chaskar R.; Chon M.C.; and Field J.B.: Time-action characteristics of regular and NPH insulin in insulin treated diabetics. *J.Clin.Endocrinol.Metab.*, 50: 475-79, 1980.
- Cahil G.F.; and McDevith H.O.: Insulin dependent diabetes mellitus: the initial lesion. *N.Engl.J.Med.*, 304: 1454-67, 1981.

- Chance R.E.; kroeff E.P.; Hoffman J.A.; and Frank B.H.: Chemical, physical, and biologic properties of biosynthetic human insulin. *Diabetes Care*, 4: 147-51, 1981.
- Colman P.G.; Nayak R.C.; Campbell I.L.; and Eisenbarth G.S.: Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipin extract. *Diabetes*, 37: 645-52, 1988.
- Cooke A.: An overview on the possible mechanisms of destruction of the insulin-producing beta cells. *Curr.Top.Microbiol.Immol.*, 164: 125-142, 1990.
- Christgau S.; Schierbeck H.; Aunstoet H.J.; and Auggard L.: Pancreatic B-cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-Kda hydrophilic form and a 64-Kda amphiphilic form which can be both membrane-bound and soluble. *J.Biol.Chem.*, 266: 21257- 21269, 1991.
- Cybulsky M.I.; Fries J.W.; and Williams A.J.: Gene structure, chromosomal location, and basis for alternative mRNA splicing of the human VCAM-1 gene. *Proce.Natl. Acad.Sci.(USA)*, 88(17): 7859-63, 1991.
- Chan B.M.C.; Elices M.J.; and Murphy E.: Adhesion to vascular cell adhesion molecule-1 and fibronectin. comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY. *J.Biol.Chem.*, 267(12): 836670, 1992.
- Clare-Salzler M.J.; Tobin A.J.; and Kaufman D.L.O.: Glutamate decarboxylase: An autoantigen in IDDM. *Diabetic Care*, 15: 132-135, 1992.
- Clark B.R.; and Keating A.: Biology of bone marrow stroma. *Ann.NY.Acad.Sci.* 770: 70, 1995.
- Cominacini L.; Fratta-Pasini A.; Garbin U.; and Davoli A.: Elevated levels of soluble E-Selectin in patients with IDDM and NIDDM relative to metabolic control. *Diabetologia*, 38 (9): 1122-24, 1995.
- Ceriello A.; Falletti E.; Bortolotti N.; and Motz E.: Increased intercellular adhesion-Molecule-1 levels in type II diabetic patients: the possible role of metabolic control and oxidative stress. *Metabolism* 45 (4): 498-501, 1996.
- Cluason P.; Alvarsson M.; and Grill V.: Enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C-peptide levels. *J-Intern-Med.*, 241(6): 493-500, 1997.
- Cominacini L.; Fratta-Pasini A.; Garbin U.; Campagnla M.; and Davoli A.: E-Selectin plasma concentration is influenced by glycemic control in NIDDM patients: Possible role of oxidative stress. *Diabetologia*, 40 (5): 584-9, 1997.
- Clausen P.; Jacobsen P.; and Rossing K.: Plasma concentrations of VCAM-1 and

ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. *Diabet-Med.*, 17 (9): 644-9, 2000.

- Chen B.H.; Chung S.B.; and Chiang W.: HLA-DR in Chinese children with type 1 diabetes mellitus. *Diabetes-Res-Clin-Prac.*, 54(1): 27-32, 2001.
- Danowski T.S.: *Diabetes Mellitus with Emphasis on Children and Young Adults.* Baltimore, Williams & Wilkins; pp.: 126-142, 1957.
- Dunn J.P.; Ipsen J.; and Elsom K.O.: Risk factors in coronary artery disease, hypertension and diabetes. *Am.J.Med.Sci.*, 259: 309-13, 1970.
- Deckert T.; Lauridsen U.B.; Madsen S.N.; and Morgensen P.: Insulin response to glucose, tolbutamide, secretin, and isoprenaline in maturity-onset diabetes mellitus. *Dan.Med.Bull.*, 19: 222-29, 1972.
- Ditzel J.; and Sandl E.: The problem of tissue oxygenation in diabetes mellitus. I. Its relation to the early functional changes in the microcirculation of diabetic subjects. *Acta.Med.Scand.*, 578 (suppl.): 49-55, 1975.
- Delprete G.F.; Betterle C.; and Padovan D.: Incidence of significance of islet-cell autoantibodies in different types of diabetes. *Diabetes* 26: 909-18, 1977.
- Davidson J.K.; and Debra D.W.: Immunologic insulin resistance. *Diabetes*, 27: 307-9, 1978.
- Diabetes Care I. (Editorial): "Control" and diabetic complications. *Diabetes Care*, 1: 204-7, 1978.
- Dunn P.J.; Cole R.A.; and Soeldner J.S.: Temporal relationships of glycosylated hemoglobin concentrations to glucose control in diabetes. *Diabetologia*, 17: 213-220, 1979.
- Delirro R.; Fusco A.; and Laura R.: Erythrocyte insulin receptors in non-insulin-dependent diabetes mellitus. *Diabetes*, 29: 96-101, 1980.
- DeFronzo R.A.: Glucose intolerance and aging. *Diabetes Care*, 4: 493-98, 1981.
- Diabetes Care. "Symposium 1981". Blood Glucose Self-Monitoring. *Diabetes Care*, 4: 492-526, 1981.
- Doniach D.; Bottazzo G.F.; and Cudworth A.G.: Etiology of type I diabetes mellitus: Heterogeneity and immunological events leading to clinical onset. *Ann.Rev.Med.*, 34: 13-23, 1983.
- Dean B.M.; Becker F.; and McNally J.M.: Insulin autoantibodies in the pre-diabetic period: Correlation with islet-cell antibodies and development of

diabetes. *Diabetologia*, 29: 339-342, 1986.

- Daw K.; Ujihara N.; Atkinson M.; and Powers A.C.: Glutamic acid decarboxylase antibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. *J.Immunol.*, 156 (2): 818-25, 1996.
- Droogan A.G.; McMillan S.A.; and Douglas J.P.: Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. *J.Neuroimmunol.*, 64(2): 185-91, 1996.
- Duits A.J.; Pieters R.C.; and Saleh A.W.: Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. *Clin.Immunol.Immunopath.*, 81(1): 96-8, 1996.
- Decochez K.; Keymeulen B.; and Somers G.: Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. *Diabetes-Care*, 23(8): 1072-8, 2000.
- Egebert U.: The blood coagulability in diabetic patients. *J.Clin.Med.*, 15: 833-36, 1963.
- Eaton R.P.; Galagan R.; and Kaufman E.: Receptor depletion in diabetes mellitus: Correction with therapy. *Diabetes Care*, 4: 229-35, 1981.
- Eisenbarth M.G.; and Jackson R.: Immunogenetics of polyglandular failure and related diseases: HLA in Endocrine and Metabolic Disorders. (In: Farid N.R. Ed.) New York, Academic Press; pp.: 235-264, 1981.
- Eisenbarth G.S.; Morris M.A.; and Searce R.M.: Cytotoxic antibodies to cloned rat islet cells in serum of patients with diabetes mellitus. *J.Clin.Invest.*, 67: 403-11, 1981.
- Ellonberg M.; and Rifkin H.: *Diabetes Mellitus. Theory and Practice.* 3rd. Ed. New Hyde Park, New York, Medical Examination Publishing Co., 1982.
- Eisenbarth G.S.: Type I diabetes: A chronic autoimmune disease. *NewEngl.J.Med.*, 314: 1360-8, 1985.
- Eisenbarth G.S.; Connelly J.; and Soeldner J.S.: The natural history of type I Diabetes mellitus. *Diabet.Metab.Rev.*, 3: 873-91, 1987.
- Etzioni A.: Immunological concepts in insulin-dependent (type I) diabetes mellitus. *Immunol.Res.*, 6: 224-51, 1987.
- Erlander M.G.; and Tobin A.J.: The structure and functional heterogeneity of

- glutamic acid decarboxylase: A review. *Neurochem.Res.*, 16: 215-26, 1991.
- Engelgau M.M.; Herman W.H.; and and Smith J.: The epidemiology of diabetes and pregnancy in the U.S.A. *Diabetes care*, 18: 1029-38, 1995.
 - Fajans S.S.; and Conn J.W.: An approach to the prediction of diabetes mellitus by modification of glucose tolerance test with cortisone. *Diabetes*, 3: 296-300, 1954.
 - Franke H.; and Fuchs J.: Eine neues antidiabetisches prinzip. *Ergebnisse klinischer untersuchungen.Dtsch.Med.Wochenschr.*, 80: 144-49, 1955.
 - Fine J.: Glucose content of normal urine. *Br.Med.J.*, 1: 1209-14, 1965.
 - Fitzgerald M.G.; and Malins J.: Ten-year follow-up report on the Birmingham Diabetes Survey of 1961. *Br.Med.J.*, 2: 35-49, 1976.
 - Feinglos M.N.; and Lebovitz H.E.: Sulfonylurea increase the number of insulin receptors. *Nature*, 276: 184-87, 1978.
 - Flier J.S.; and Roth J.: Diabetes Mellitus: Clinical pharmacology: Basic Principles in Therapeutics (Introduction In: Melon K.L.; and Morelli H.F. Eds.): 2nd. Ed. New York, Macmillan Publishing Co.; pp.: 515-523, 1978.
 - Freidenberg G.R.; White N.; and Cataland S.: Diabetes responsive to intravenous but not subcutaneous insulin: Effectiveness of aprotinin. *N.Engl.J.Med.*, 305: 363-73, 1981.
 - Fineberg S.E.; Galloway J.A.; and Fineberg N.S.: Safety, efficacy, and immunogenicity of human insulin of recombinant DNA origin. *Diabetes*, 2: 35-41, 1982.
 - Foster D.W.: Diabetes Mellitus: The Metabolic Basis of Inherited Disease (In: Stanbury J.B.; Wyngaarden J.P.; and Fredrickson D.S. Eds.): 5th. Ed. New York, McGraw-Hill Book Co.; pp.: 99-117, 1983.
 - Feuerbach D.; and Feyen J.H.M.: Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis. *FEBS Lett.*, 402(1): 21-4, 1997.
 - Grodsky G.M.; Batts A.A.; and Bennett L.L.: Effects of carbohydrates on secretion of insulin from the isolated rat pancreas. *Am.J.Physiol.*, 205: 638-45, 1963.
 - Goore H.G.; and Randle P.I.: Regulation of insulin secretion studies with pieces of rabbit pancreas incubated in vitro. *Biochem.J.*, 93: 66-68, 1964.
 - Gregersen G.: Diabetic neuropathy: Influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. *Neurology*, 17: 972-84, 1967.

- Greider M.H.; Howell S.L.; and Lacy P.E.: Isolation and properties of secretory granules from rat islets of Langerhans. II. Ultrastructure of the beta granule. *J.Cell.Biol.*, 41: 162-71, 1969.
- Grant P.T.; and Combs T.L.: Proinsulin, a biosynthetic precursor of insulin. *Biochemistry*, 6: 69-76, 1970.
- Goodner C.J.; and Porte D.E.: Determinants of basal islet secretion in man. *Handbook of Physiology, and Endocrinology* (In: Steiner D.F.; and Freinkel N. Eds.); I. Baltimore, Williams & Wilkins; pp.: 597, 1972.
- Gavin J.R.; Roth J; and Neville D.M.: Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. *Proc.Natl.Acad.Sci. (USA)*, 71: 84-90, 1974.
- Goldberg M.F.: The role of ischemia in the production of vascular retinopathies: Diabetic retinopathy (In: Lynn J.R.; Synder W.B.; and Vaiser A. Ed.): New York, Grane & Stratton; pp.: 47-63, 1974.
- Gavin J.R.; Kahn C.R.; and Gorden R.: Radioreceptor assay of insulin: Comparison of plasma and pancreatic insulin and proinsulin. *J.Clin.Endocrinol.Metab.*, 41: 438-45, 1975.
- Greene D.A.; DeJesus P.V.; and Jr.Winegrad A.F.: Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. *J.Clin.Invest.*, 55: 1326-33, 1975.
- Gabbay K.H.; Hasty K.; and Breslow J.L.: Glycosylated hemoglobin and long-term blood glucose control in diabetes mellitus. *J.Clin.Endocrinol.Metab.*, 44: 859-68, 1977.
- Ganda O.P.; Soeldner J.S.; and Gleason R.E.: Monozygotic triplets with discordance for diabetes mellitus and diabetic microangiopathy. *Diabetes*, 26: 469-74, 1977.
- Galloway J.A.; and Bressler R.: Insulin treatment in diabetes. *Med.Clin.N.Am.*, 62: 663-80, 1978.
- Gliedman M.L.; Tellis V.A.; and Soberman R.: Long-term effects of pancreatic transplant function in patients with advanced juvenile-onset diabetes. *Diabetes Care*, I: 1-11, 1978.
- Gonen E.; and Rubenstein A.H.: Hemoglobin A1 and diabetes mellitus. *Diabetologia*, 15: 108-119, 1978.
- Gabbay K.H.; Sosenko J.M.; and Banuchi G.A.: Glycosylated hemoglobins: Increased glycosylation of hemoglobin A in diabetic patients. *Diabetes*, 28: 337-44, 1979.

- Goeddel D.V.; Kleid D.G.; and Bolivar F.: Expression in *Escherichia coli* of chemically synthesized genes for human insulin. *Proc.Natl.Acad.Sci.(USA)*, 76: 106-115, 1979.
- Graf R.J.; Halter J.B.; Halar E.; and Porte D.: Nerve conduction abnormalities in untreated maturity-onset diabetes mellitus: relation to levels of fasting plasma glucose and glycosylated hemoglobin. *Ann.Intern.Med.*, 90: 298-301, 1979.
- Graf R.J.; Halter J.P.; Pfeifer M.; and Halar E.: The influence of glycemic control on nerve conduction abnormalities in diabetics. *Diabetes*, 28: 387-91, 1979.
- Gandolfo G.M.; deAngelis A.; and Torresi M.V.: Determination of antithrombin III activities by different methods in diabetic patients. *Haemostasis*, 9: 15-19, 1980.
- Goldstein D.E.; Walker B.; and Rawlings S.S.: Hemoglobin A1c levels in children and adolescents with diabetes mellitus. *Diabetic Care*, 3: 503-11, 1980.
- Gepts W.; and LeCompte P.M.: The pancreatic islets in diabetes. *Am.J.Med.*, 70: 105-117, 1981.
- Gorsuch A.N.; Lister J.; and Dean B.M.: Evidence for a long-prediabetic period in type I (insulin-dependent) diabetes mellitus. *Lancet*, 1: 1363-67, 1981.
- Gorsuch A.N.; Spencer K.M.; and Lister J.: Evidence for a long-prediabetic period in Type I (insulin-dependent) diabetes mellitus. *Lancet*, 2: 1363-66, 1981.
- Giorda R.; Peakman M.; and Tan K.C.: Glutamic acid decarboxylase expression in islets and brain. *Lancet*, 1: 1469-1470, 1991.
- Galtier-Dereure F.; Biron C.; and Vies M.: Vascular complications of diabetes mellitus: What role for phospholipid-binding antibodies? *Lupus*, 7 (7): 469-74, 1998.
- Howell S.L.: Role of ATP in the intracellular translocation of proinsulin and insulin in the rat pancreatic beta cell. *Nature (New Biol.)*, 235: 85-89, 1972.
- Heding L.; and Rasmussen J.: Human C-peptide in Normal and Diabetic Subjects. *Diabetologia*, 11: 201-12, 1975.
- Horwitz D.: Proinsulin, insulin and C-peptide concentrations in human portal and peripheral blood. *J.Clin.Invest.*, 55: 1278-83, 1975.
- Huang S.W.; and MacLaren N.J.: Insulin-dependent-diabetes mellitus: a disease of autoaggression. *Science*, 192: 64-69, 1976.
- Holman R.R.; and Turner R.C.: Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes mellitus. *Diabetes*, 28: 227-33, 1979.

- Holle A.; Mangels W.; and Dreyer M.: Biguanide treatment increases the number of insulin-receptor sites on human erythrocytes. *N.Engl.J.Med.*, 305: 563-66, 1981.
- Howard M.J.; Hidaka H.; and Ishibashi F.: Type II diabetes and insulin resistant: evidence of lack of inherent cellular defects in insulin sensitivity. *Diabetes*, 30: 562-67, 1981.
- Hidaka H.; Nagulesparan M.; and Kimes I.: Improvement of insulin secretion but not insulin resistant after short-term control of plasma glucose in obese type II diabetics. *J.Clin.Endocrinol.Metab.*, 54: 217-22, 1982.
- Harrison L.C.; Campbell I.L.; and Colman P.C.: Type I diabetes: Immunology and Immunotherapy. *Adv.Endocrinol.Metab.*, 1: 35-94, 1990.
- Hemler M.E.: VLA proteins in the integrin family: structures, functions, and their role on leukocytes. *Annu.Rev.Immunol.*, 8: 365-80, 1990.
- Hession R.; Tizard R.; and Vassallo C.: Cloning of an alternative form of vascular cell adhesion molecule-1 (VCAM-1). *J.Biol.Chem.*, 266(11): 6682-5, 1991.
- Hession R.; Moy P.; and Tizard R.: Cloning of murine and rat vascular cell adhesion molecule-1. *Biochem.Biophys.Res.Comm.*, 183(1): 163-9, 1992.
- Harris M.I.; Couric C.C.; and Reiber G.: Diabetes in American (2nd Ed.); Washington. DC, U.S. Gout. Printing Office (NIH publ. No 95-1468), 1995.
- Hermitte L.; Atlan-Gepner C.; Mattei C.; and Dufayet D.: Diverging evaluation of anti-GAD and anti-IA-2 antibodies in long-standing diabetes mellitus as a function of age at onset.: no association with complications. *Diabet-Med.*, 15 (7): 586-91, 1998.
- Haupt E.; Haupt A.; and Herrmann R.: The KID Study V: the natural history of type 2 diabetes in younger patients still practicing a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. *Exp-Clin-Endocrinol-Diabetes*, 107(4): 236-43, 1999.
- Hovorka R.; Albarrak A.; and Chassin L.: Relationship between beta-cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting type 2 diabetes mellitus. *Diabet-Med.*, 18(10): 797-802, 2001.
- Ipsen J.; Clark T.W.; and Elsom K.V.: Diabetes and heart disease: Periodic health examination programs. *Am.J.Public Health*, 59: 1595-99, 1969.
- Irvine W.J.; and Barnes E.W.: Addison's disease, ovarian failure and hypothyroidism. *Clin.Endocrinol.Metab.* 4: 379-87, 1975.

- Irvine W.J.; Gray R.S.; and McCallum C.J.: Pancreatic islet cell antibody as a marker for asymptomatic and latent diabetes and prediabetes. *Lancet*, 2: 1097-1105, 1976.
- Irvine W.J.; McCallum C.J.; and Gray R.S.: Pancreatic islet-cell antibodies in diabetes mellitus correlated with duration and type of diabetes, coexistent autoimmune disease and HLA type. *Diabetes*, 26: 138-60, 1977.
- Irvine W.J.; McCallum C.J.; Gray R.S.; and Duncan L.P.I.: Clinical and pathogenic significance of pancreatic islet-cell antibodies in diabetics treated with oral hypoglycemic agents. *Lancet*, 1: 1025-33, 1977.
- Irvine W.J.; Sawers J.S.A.; and Feek C.M.: The value of islet-cell antibody in predicting secondary failure of oral hypoglycemic agent therapy in diabetes mellitus. *J.Clin.Lab.Immunol.*, 2: 23-29, 1979.
- Irvine W.J.; Gray R.S.; and Steel J.M.: Islet cell antibody as a marker for early stage Type 1 diabetes. (In: *The immunology of diabetes* ; Irvine W.J.; and Teviot, Edinburgh), pp.: (117-154), 1980.
- Imagawa A.; Itoh N.; and Hanafusa T.: High prevalence of antibodies to glutamic acid decarboxylase in comparison to islet cell antibodies in patients with long-standing insulin-dependent diabetes mellitus. *Res-Commun-Mol-Pathol-Pharmacol.*, 92 (1): 43-52, 1996.
- Inguchi T.; Umeda F.; and Kakimoto M.: Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. *Endoc-J.*, 47(6): 763-70, 2000.
- Jarrett R.J.; and Keen H.: Hyperglycemia and diabetes mellitus. *Lancet*, 2: 1009-14, 1976.
- Jarrett R.J.; Keen H.; and Fuller J.H.: Worsening to diabetes in men with impaired glucose intolerance. *Diabetologia*, 16: 25-28, 1979.
- Jovanovic L.; and Peterson C.M.: Clinical utility of glycosylated hemoglobin. *Am.J.Med.*, 70: 331-38, 1981.
- Johnson R.N.; Metcalf P.A.; and Baker J.R.: Fructosamine: a new approach to the estimation of serum glycosylation. An index of diabetic control. *Clin.Chem.Act.*, 127: 87-95, 1982.
- Jury K.M.; Loeffler D.; and Eiermann T.H.: Evidence for somatic mutation and affinity maturation of diabetes associated human autoantibodies to glutamate decarboxylase. *J.Autoimmun.*, 9 (3): 371-7, 1996.
- Jude E.B.; Abbott C.A.; and Young M.: The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. *Diabetologia*, 41 (3):

330-6, 1998.

- Knowles H.C.; Guest Jr.; and Lamp G.M.: The course of juvenile diabetes treated with unmeasured diet. *Diabetes*, 14: 239-41, 1965.
- Katsoyannis P.G.; Temotsko A.; and Zalut C.: Insulin peptides XII. Human insulin generation by combination of synthetic A and B chains. *J. Am. Chem. Soc.*, 88: 166-69, 1966.
- Kung Y.T.; Da Y.C.; and Huang W.T.: Total synthesis of crystalline insulin. *Sci. Sinica (Peking)*, 15: 544-49, 1966.
- Kannel W.B.; Brand N.; and Skinner J.J.: The relation of adiposity to blood pressure and development of hypertension (The Framingham Study). *Ann. Intern. Med.*, 67: 48-54, 1967.
- Kipnis D.M.: Insulin secretion in diabetes mellitus. *Ann. Intern. Med.*, 69, 891-9, 1968.
- Kemmler W.; and Steiner D.F.: Conversion of proinsulin to insulin in a subcellular fraction from rat islets. *Biochem. Biophys. Res. Commun.*, 41: 1223-7, 1970.
- Kemp C.B.; Knight M.J.; and Scharp D.W.: Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. *Diabetologia*, 9: 486-88, 1973.
- Kamenetzki S.A.; Bennett P.H.; and Dippe S.E.: A clinical and histologic study of diabetic nephropathy in the Pima Indians. *Diabetes*, 23: 61-64, 1974.
- Kohner E.M.; and Oakley N.W.: Diabetic retinopathy. *Metabolism*, 24: 1085-9, 1975.
- Koenig R.J.; Peterson C.M.; and Jones R.L.: Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. *N. Engl. J. Med.*, 295: 417-21, 1976.
- Koenig R.J.; Peterson C.M.; and Kilo C.: Hemoglobin A1c as an indicator of the degree of glucose intolerance in diabetes. *Diabetes*, 25: 230-4, 1976.
- Kohner E.M.: The problems of retinal blood flow in diabetes. *Diabetes*, 25 (Suppl.2): 839-41, 1976.
- Koenig R.J.; Blobstein S.H.; and Cerami A.: Structure of carbohydrate of hemoglobin A1c. *J. Biol. Chem.*, 252: 2992-9, 1977.
- Kaldany A.: Autoantibodies to islet cells in diabetes mellitus. *Diabetes*, 28: 102-5, 1979.

- Kahn C.R.: The role of insulin receptors in insulin resistance states. *Metabolism*, 29: 455-58, 1980.
- Kahn C.R.; and Flier J.S.: Immunologic aspects of endocrine disease. (Clinical Immunology Vol.2 Philadelphia, Saunders Co.W.B.; In Parker C.W. Ed.), pp.: 815-866, 1980.
- Koenig R.J.; and Cerami A.: Hemoglobin A1c and diabetes mellitus. *Ann.Rev.Med.*, 31: 29-34, 1980.
- Kahn C.R.; Baird K.L.; and Flier J.S.: Insulin receptors, receptor-antibodies, and the mechanism of insulin action. *Rec.Prog.Hor.Res.*, 37: 477-83, 1981.
- Kolterman O.G.; Gray R.S.; and Griffin J.: Receptor and post-receptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. *J.Clin.Invest.*, 68: 957-61, 1981.
- Krolewski A.S.; Czyzyk A.; and Kopczynski J.: Prevalence of diabetes mellitus, coronary heart disease and hypertension in the families of insulin-dependent and insulin-independent diabetics. *Diabetologia*, 21: 520-24, 1981.
- Keen H.; Jarrett R.J.; and McCartney P.: The ten-year follow up of the Bedford survey (1962-1972); glucose tolerance and diabetes. *Diabetologia*, 22: 73-75, 1982.
- Komalesh M.; Karasik A.; and Srikanta S.: Islet cell antibodies as predictors of insulin-dependent diabetes mellitus. *Pract.Cardiol.*, 12: 79-91, 1986.
- Kaufman D.L.; and Tobin A.J.: Glutamate decarboxylases and autoimmunity in insulin-dependent diabetes mellitus. *Trends in Pharmacological Sciences*, 14: 107-109, 1993.
- Kim J.; Richter W.; and Anastoot H.J.: Differential expression of GAD 65 and Gad 67 in humans, rat and mouse pancreatic islets. *Diabetes*, 42: 1799-1808, 1993.
- Kansas G.S.: Selectins and their ligands: Current concept and controversies. *Blood*, 88: 3259-71, 1996.
- Kasuga A.; Maruyama T.; and Ozawa Y.: Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin dependent diabetes mellitus in Japanese. *J.Autoimmun.*, 9 (1): 105-11, 1996.
- Kawasaki E.; Yano M.; and Abiru N.: Detection of recombinant GAD65 and GAD67 antibodies using a simple radioimmunoassay. *Diabetes Res.Clin. Pract.*, 32 (1-2): 61-9, 1996.
- Koga M.; Otsuki M.; and Kuba M.: Relationship between circulating

vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. *Diabetes.Med.*, 15 (8): 661-7, 1998.

- Kopp H.P.; Hopmeier P.; and Schernthaner G.: Concentrations of circulating P-selectin are increased in patients with newly diagnosed insulin-dependent diabetes mellitus. *Exp.Clin.Endocrinol.Diabetes*, 106 (1): 41-4, 1998.
- Kado S.; and Nagata N.: Circulating intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus. *Diabetes-Res-Clin-Pract.*, 46(2): 143-8, 1999.
- Loubatieres A.: The mechanism of action of hypoglycemic sulfonamides. A concept based on investigations in animals and in man. *Diabetes*, 6: 408-13, 1957.
- Loubatieres A.: I. Analysis of the beta-cytotropic action of the hypoglycemic Sulfonamides: Basis for its use in the treatment of diabetes. *Presse.Med.*, 68: 1421-24, 1960.
- Lillehei R.C.; Idezuki Y.; and Feemster J.A.: Transplantation of stomach, intestine, and pancreas: Experimental and clinical observations. *Surgery*, 62: 721-29, 1967.
- Lacy P.E.; Howell S.L.; Young D.A.; and Fink C.J.: New Hypothesis of insulin secretion. *Nature*, 219: 1177-88, 1968.
- Levine R.; and Pfeiffer E.F.: HB 419: A new oral antidiabetic drugs (Paper presented at the Tegernsee Conference, in Rottach-Egern, Germany, January 27-29, 1969). *Horm.Metab.Res.*, 1 (suppl.1): 1-92, 1969.
- Lir B.J.; and Haist R.E.: Insulin biosynthesis: Effects of carbohydrates and related compounds. *Can.J.Physiol.Pharmacol.*, 47: 791-802, 1969.
- Leonard R.J.; Lazarow A.; and Hegre O.D.: Pancreatic islet transplantation in the rat. *Diabetes*, 22: 413-16, 1973.
- Little H.L.; Sacks A.H.; and Krupp M.: Abnormal hemorrheology in the pathogenesis of diabetic microangiopathy. *Cong.Int.Diab.Fed.8th*, 280: 176-9, 1973.
- Lacy P.E.; Finke E.H.; and Codilla R.C.: Cinemicrographic studies on beta-cell granule movement on monolayer culture of islet-cells. *Lab.Invest.*, 33: 570-4, 1975.
- Landrum R.; Walker G.; and Cudworth A.G.: Islet-cell antibodies in diabetes mellitus. *Lancet*, 2: 1273-76, 1976.
- Lillehei R.C.; Ruiz J.O.; and Acquino C.: Transplantation of the pancreas.

Acta.Endocrinol., (Kbhi) 83 (Suppl. 205): 303-9, 1976.

- Lomedico P.T.; and Saunders G.F.: Preparation of pancreatic mRNA: Cell-Free translation of an insulin-immunoreactive polypeptide. *Nucleic Acids Res.*, 3: 381-5, 1976.
- Little H.; and Sacks A.: Role of abnormal blood rheology in the pathogenesis of diabetic retinopathy. *Tr.Am.Acad.Ophth.Otol.*, 83: 522-4, 1977.
- Little H.; Sacks A.; Vassiliadis A.; and Greer R.: Current concepts on pathogenesis of diabetic retinopathy: a dysproteinemia, *Tr.Am.Ophth.Soc.*, 75: 397-401, 1977.
- Leibowitz Z.: The Framingham Eye Study: Diabetic retinopathy Survey. *Ophthalmol.*, 24 (Suppl. May-June): 401-4, 1980.
- Lowe G.D.O. Lowe J.M.; and Drummond M.M.: Blood viscosity in young male diabetics with and without retinopathy. *Diabetologia*, 18: 359-65, 1980.
- Lester F.T.: Long-standing diabetes mellitus in Ethiopia: a survey of 105 patients. *Diabetologia*, 25: 222-5, 1983.
- Lloyd D.; and Marples J.: Simple colorimetry of glycated serum protein in a centrifugal analyser. *Clin.Chem.*, 30: 1686-1688, 1984.
- Lampeter E.R.; Kishimoto T.K.; and Rothlein R.: Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. *Diabetes*, 41 (12): 1668-71, 1992.
- Lasky L.A.: Selectins: Interpreters of cell-specific carbohydrate information during inflammation. *Science*, 258: 964-7, 1992.
- Langer O.; Rodirigues D.A.; and Xenakis E.M.J.: Intensified versus conventional management of gestational diabetes. *Am.J.Obstet.Gynecol.*, 170: 1036-40, 1994.
- Lohmann T.; Leslie R.D.; and Londei M.: T-cells clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. *J.Autoimmun.*, 9 (3): 385-9, 1996.
- Ludvigsson J.; and Hellstrom S.: Autoantibodies in relation to residual insulin secretion in children with IDDM. *Diabetes-Res-Clin-Pract.*, 35 (2-3): 81-9, 1997.
- Landin-Olsson M.; Arnqvist H.J.; and Blohme G.: Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus. *Autoimmunity*, 29 (1): 57-63, 1999.
- Littorin B.; Sundkvist G.; and Hagopian W.: Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetics predict the need for

insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassified diabetes. *Diabetes Care*, 22 (3): 409-12, 1999.

- Lee Y.S.; Ng W.Y.; and Thai A.C.: Prevalence of ICA and GAD antibodies at initial presentation of type 1 diabetes mellitus in Singapore children. *J-Pediatr-Endocrinol-Metab.*, 14(6): 767-72, 2001.
- Lohmann T.; Kellner K.; and Verlohren H.J.: Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). *Diabetologia*, 44(8): 1005-10, 2001.
- Maclean N.; and Oglivie R.F.: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. *Diabetes*, 4: 367-71, 1955.
- Munger B.L.: A light and electron microscopic study of cellular differentiation in the pancreatic islets of the mouse. *Am.J.Anat.*, 103: 275-8, 1958.
- Meienhofer J.; Schnabel E.; and Bremer H.: Synthese der Insulinketten und ihr Kombination zu insulinaktiven preparaten. *Z.Naturforsch*, 18: 1120-3, 1963.
- Matthews E.K.: Electrical activity in islet cells and insulin secretion. *Acta Diabetol.Lat.*, 7 suppl.1: 3506-9, 1970.
- Morris G.E.; and Korner A.: The effect of glucose on insulin biosynthesis by isolated islets of Langerhans of the rat. *Biochim.Biophys.Acta*, 208: 404-8, 1970.
- Motschinsky F.M.; Ellerman J.E.; and Krazanowski J.: The dual function of glucose in islets of Langerhans. *J.Biol.Chem.*, 246: 1007-9, 1971.
- Miki E.; Kuzuya T.; and Ide T.: Frequency, degree, and progression with time of proteinuria in diabetic patients. *Lancet*, 1: 922-4, 1972.
- Mauer S.M.; Sutherland D.E.R.; and Steffes M.W.: Pancreatic islet transplantation: effects on the glomerular lesions of experimental diabetes in the rat. *Diabetes*, 23: 748-53, 1974.
- McMillan D.E.: Disturbance of serum viscosity in diabetes mellitus. *J.Clin.Invest.*, 53: 1071-4, 1974.
- Mitchell A.A.: Relation between insulin-induced hypoglycemia and serum haptoglobin level. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. *Diabetes*, 23: 151-3, 1974.
- MacCuish A.C.; and Irvine W.J.: Autoimmunological aspects of diabetes mellitus. *Clin.Endocrinol.Metab.*, 4: 435-9, 1975.

- Mauer S.M.; Steffes M.W.; and Sutherland D.E.R.: Studies of the rate of regression of the glomerular lesions of diabetic rats treated with pancreatic islet transplantation. *Diabetes*, 24: 280-5, 1975.
- McMillan D.E.: Two roles for plasma fibrinogen in the production of diabetic microangiopathy. *Diabetes*, 24 (Suppl.2): 438-41, 1975.
- Moorhouse J.A.: Diabetic peripheral neuropathy. In Fajans S.S. (Ed.). *Diabetes Mellitus*. DHEW Publ.No. (NIH) 56-854, Bethesda, Md. National Institutes of Health; pp.: 243-255, 1976.
- Matas A.J.; Payne W.D.; and Grotting J.C.: Portal versus systemic transplantation of dispersed neonatal pancreas. *Transplantation*, 24: 333-6, 1977.
- McDonald M.J.; Shapiro R.; and Bleichman M.: Glycosylated minor components of human adult hemoglobin. Purification, identification, and partial structure analysis. *J.Biol.Chem.*, 253: 2327-31, 1978.
- Monnier L.; Follea G.; and Mirouze J.: Antithrombin III deficiency in diabetes mellitus: influence in vascular degenerative complications. *Horm.Metab.Res.*, 10: 470-2, 1978.
- McDonald J.; and Davis J.E.: Glycosylated hemoglobins and diabetes mellitus. *Human Pathology*, 10: 279-91, 1979.
- Menard L.; Dempsey M.E.; and Blankstein L.A.: Quantitative determination of glycosylated hemoglobin A1 by agar gel electrophoresis. *Clin.Chem.*, 26: 1598-1601, 1980.
- Mitchell P.: The prevalence of diabetic retinopathy: a study of 1300 diabetics from New Castle and the Hunter Valley. *Aust.J.Ophthalmol.*, 8: 241-4, 1980.
- Miller E.; Hare J.W.; and Cloherty J.: Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. *N.Engl.J.Med.*, 304: 1331-1334-7, 1981.
- Miedema K; and Casparie T.: Glycosylated hemoglobins: Biochemical evaluation at clinical utility. *Ann.Clin.Biochem.*, 21: 2-15, 1984.
- Maclaren N.K.: How, when, and why to predict IDDM. *Diabetes*, 37: 1591-1594, 1988.
- Moy P.; Lobb R.; and Tizard R.: Cloning of an inflammation-specific phosphatidyl inositol-linked form of murine vascular cell adhesion molecule-1. *J.Biol.Chem.*, 268(12): 8835-41, 1993.
- Matsuda M.; Tsukada N.; and Miyagi K.: Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients

with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. *J.Neuroimmunol.*, 59(1-2): 35-40, 1995.

- Meng H.; Marchese M.J.; and Garlick J.A.: Mast cell include T-cell adhesion to human fibroblasts by regulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. *J.Invest.Dermatol.*, 105(6): 789-96, 1995.
- Myers M.A.; Rabin D.U.; and Rowley M.J.: Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. *Diabetes*, 44 (11): 1290-5, 1995.
- McDaniel M.L.; Kwon G.; and Hill J.R.: Cytokines and nitric oxide in islet cell inflammation and diabetes. *Proc.Soc.Exp.Biol.Med.*, 211 (1): 2432-4, 1996.
- Mehta H.B.; Vold B.S.; and Minkin S.: Sensitive non-isotopic assay for GAD65 autoantibodies, a key risk-assessment marker for insulin-dependent diabetes mellitus. *Clin.Chem.*, 42 (2): 263-9, 1996.
- Matsumoto K.; Nakamura H.; and Ueki Y.: Correction of hyperglycemia reduces insulin resistance and serum soluble E-Selectin levels in patients with type 2 diabetes mellitus. *Diabet-Med.*, 18(3): 224-8, 2001.
- Matsumoto K.; Sera Y.; and Nakamura H.: Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. *Diabetes-Res-Clin-Pract.*, 55(2): 131-8, 2002.
- Navarrete V.N.; and Torres I.H.: A triamcinolonic-glucose tolerance test in the early diagnosis of diabetes mellitus. *Diabetes*, 14: 481-3, 1965.
- Nerup J.; Andersen; and Bendixen C.T.: Anti-pancreatic cellular hypersensitivity in diabetes mellitus. *Diabetes*, 20: 424-7, 1971.
- Nerup J.; Andersen O.; and Christy M.: HLA autoimmunity, virus, and the pathogenesis of juvenile diabetes mellitus. *Acta Endocrinol.*, 83 (Suppl.205): 167-79, 1976.
- National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes*, 28: 1039-56, 1979.
- Neufeld M.; Maclaren N.K.; and Riley W.J.: Islet cell and other specific antibodies in U.S. Caucasians and Blacks with insulin-dependent diabetes mellitus. *Diabetes*, 29: 589-93, 1980.
- Nathan D.M.; Lou P.; and Avruch J.: Intensive conventional and insulin pump therapies in adult type I diabetics. *Ann.Intern.Med.* 97: 31-6, 1982.
- Niskanen L.K.; Tuomi T.; and Karjalainen J.: GAD antibodies in NIDDM.

Ten-Year follow-up from the diagnosis. *Diabetes Care*, 18 (12): 1557-65, 1995.

- Naserke H.E.; Ziegler A.G.; and Lampasona V.: Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type I diabetes. *J.Immunol.*, 161 (12): 6963-9, 1998.
- O'Sullivan J.P.; and Mahan C.M.: Prospective study of 352 young patients with chemical diabetes. *N.Engl.J.Med.*, 278: 1038-44, 1968.
- Osterby R.: Diabetic glomerulopathy. A quantitative electron microscopic study of the initial phases. In: Rodriguez R.R.; and Vallance-Owen J. (Eds.): *Proceedings of the Seventh Congress of the International Diabetes Federation*. Buenos Aires, 23-28 August 1970. Amsterdam Excerpta Medica; PP.: 793-803, 1971.
- Oyer P.E.; Cho S.; and Petersen J.D.: Studies on human proinsulin. Isolation and amino acid sequence of human pancreatic C-peptide. *J.Biol.Chem.*, 246: 1375-89, 1971.
- Osterby R.: Kidney structural abnormalities in early diabetes. In: Camerini-Davalos R.A.; and Cole H.S. (Eds.): *Vascular and Neurological Changes in Early Diabetes*. New York Academic Press; pp.: 323-340, 1973.
- Olefsky J.M.; and Reaven G.M.: Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. *Am.J.Med.*, 60: 89-92, 1976.
- Ostrander L.D.; and Lamphiear D.E.: Coronary risk factors in a community. Findings in Tecumseh, Michigan. *Circulation*, 53: 152-60, 1976.
- Olefsky J.M.; and Reaven G.M.: Insulin binding in diabetes, relationships with plasma insulin levels and insulin sensitivity. *Diabetes*, 26: 680-9, 1977.
- Olefsky J.M.; and Ciaraldi T.P.: The insulin receptor: basic characteristics and its role in insulin resistant states. In: Brownlee M. (Ed.): *Diabetes Mellitus. Islet cell function/Insulin action*. Vol. II. New York, Garland. STPM Press; pp.: 73-116, 1981.
- Owens D.R.; Jones M.K.; and Haynes T.M.: Human insulin study of safety and efficacy in man. *Br.Med.J.*, 282: 1264-7, 1981.
- Orci L.: Macro- and microdomains in the endocrine pancreas. *Diabetes*, 31: 538-44, 1982.
- Orci L.; Vassali J.; and Parrelet A.: The insulin factory. *Sci.Amer.*, 261: 85-94, 1988.

- Osborn L.; Hession C.; and Tizard R.: Direct expression cloning of vascular cell adhesion molecule-1, a cytokine-induced endothelial protein that binds to lymphocytes. *Cell*, 59(6): 1203-11, 1989.
- O'Sullivan J.B.: Diabetes after GDM. *Diabetes*, 40 (Suppl.2): 131-4, 1991.
- Otsuki M.; Hashimoto K.; and Morimoto Y.: Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. *Diabetes*, 46 (12): 2096-3001, 1997.
- Perley M.; and Kipnis D.M.: Plasma insulin response to glucose and tolbutamide of normal weight and obese diabetic and non-diabetic subjects. *Diabetes*, 15: 867-73, 1966.
- Permutt M.A.; and Kipnis D.M.: Insulin biosynthesis. I. On the mechanism of glucose stimulation. *J.Biol.Chem.* 247: 1194-1212, 1972.
- Palade G.: Intracellular aspects of the process of protein synthesis. *Science*, 189: 347-52, 1975.
- Palmer J.P.; Benson J.W.; and Walter R.M.: Arginine stimulate acute phase of insulin and glucagon secretion in diabetic subjects. *J.Clin.Invest.*, 58: 565-69, 1976.
- Palumbo P.J.; and Labarth D.R.: The incidence of diabetes mellitus. *Advances in Metabolic disorders* (In Rochester, Minnesota, 1945-1969; in Levine R.; and Luft R. Eds.); New York, Academic Press; pp.: 13-28, 1978.
- Pipeleers D.G.; Pipeleers-Marichal M.A.; and Karl J.E.: Secretory capability of islets transplanted intraportally in the diabetic rat. *Diabetes*, 27: 817-22, 1978.
- Pettitt D.J.; Knowler W.C.; and Lisse J.R.: Development of retinopathy and proteinuria in relation to plasma glucose concentrations in Pima Indians. *Lancet*, 2: 1050-6, 1980.
- Podolsky S.; and Viswanathan M.: *Secondary Diabetes. The Spectrum of the Diabetic Syndromes*. New York, Raven Press, 1980.
- Prince M.J.; and Olefsky J.M.: Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. *J.Clin.Invest.*, 66: 608-11, 1980.
- Pedersen O.; and Hjollund E.: Insulin receptor binding to fat and blood cells and insulin action in fat cells from insulin-dependent diabetes mellitus. *Diabetes*, 31: 706-9, 1982.
- Poussier P.; Nakhooda A.F.; and Jalk J.A.: Lymphopenia and abnormal lymphocyte subsets in the "BB" rat: relationship to the diabetic syndrome. *Endocrinology*, 110: 1825-8, 1982.

- Palmer J.P.; Aspilin C.M.; and Clemons J.: Insulin antibodies in insulin-dependent diabetics before insulin treatment. *Science*, 222: 1337-1339-43, 1983.
- Palmer J.P.: Insulin autoantibodies: Their role in pathogenesis of IDDM. *Diab.Metab.Rev.*, 3: 1005-1015, 1987.
- Pigott R.; Dillon L.P.; and Hemingway I.H.: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. *Biochem.Biophys.Comm.*, 187(2): 584-9, 1992.
- Pankewycz O.G.; Guan J.X.; and Benedict J.F.: Cytokines as mediators of autoimmune diabetes and diabetic complications. *Endocr.Rev.*, 16 (2): 164-76, 1995.
- Physician's Guide to Non-Insulin-Dependent(Type 11) Diabetes: Diagnosis and treatment, 3rd ed. Alexandria VA, American Diabetes Association 1998. A monograph that reviews the diagnosis, pathogenesis, and treatment of type 2 diabetes, 1998.
- Pietropaolo M.; Peakman M.; and Pietropaolo L.S.: Combined analysis of GAD65 and ICA512 (IA-2) autoantibodies in organ and non-organ-specific autoimmune diseases confers high specificity for insulin-dependent diabetes mellitus. *J.Autoimmun.*, 11 (1): 1-10, 1998.
- Renold A.E.; Winegrad A.I.; and Froesch E.R.: Sulfonylurea Symposium: Studies on the site of action of arylsulfonylureas in man. *Metabolism*, 5: 757-59, 1956.
- Remain Q.R.; and Wilkerson H.L.C.: The efficiency of screening tests for diabetes. *J.Chron.Dis.*, 13: 6-11, 1961.
- Rabhar S.: An abnormal hemoglobin in red cells of diabetics. *Clin.Chim.Acta*, 22: 296-302, 1968.
- Rubenstein A.H.; Melani F.; and Pilkis S.: Proinsulin: secretion, metabolism, immunological and biological properties. *Postgr.Med.J.*, 45 (Suppl.1): 476-85, 1969.
- Rado J.P.: Investigation of the diuretic effect of glibenclamide in healthy subjects and in patients with pituitary and nephrogenic diabetes insipidus. *Horm.Metab.Res.*, 6: 289-94, 1974.
- Rubenstein A.H.; Kuzuya H.; and Horowitz D.L.: Clinical significance of circulating C-peptide in diabetes mellitus and hypoglycemic disorders. *Arch.Intern.Med.*, 137: 625-29, 1977.
- Root H.F.; Gorman C.K.; and Szabo A.J.: The natural history of diabetes.

II. Morbidity due to micro and macro-vascular complications. Unpublished data, 1979.

- Rizza R.A.; Gerich J.E.; and Haymond M.W.: Control of blood sugar in insulin-dependent diabetics: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. *N.Engl.J.Med.*, 303: 1313-16, 1980.
- Rendell M.: Expanding clinical use of C-peptide radioimmunoassay. *Acta Diabetol.Lat.*, 20: 105-13, 1983.
- Rendell M.: C-peptide levels as a criterion in treatment of maturity-onset diabetes. *J.Clinical Endocrinology and Metabolism*, 57 (6): 1198-201, 1983.
- Riley W.J.; MacLaren N.K.; and Silverstein J.H.: The predictability of insulin-dependent diabetes mellitus. *Adv.Pediatr.*, 35: 167-187, 1988.
- Rossini A.A; Mordes J.P.; and Handler E.S.: A "Tumbler" hypothesis: the autoimmunity of insulin-dependent diabetes mellitus. *Diabet.Spect.*, 2: 195-201, 1989.
- Ruoslahti E.: Integrins. *J.Clin.Invest.*, 87: 1-9, 1991.
- Roep B.O.; Heidenthal E.; and de-Vries R.R.: Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. *Lancet*, 35: 343 (8913): 1590-3, 1994.
- Rudy G.; Stone N.; and Harrison L.C.: Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase stimulate T-cells of individuals at risk for insulin-dependent diabetes. *Mol.Med.*, 1 (6): 625-33, 1995.
- Roll U.; Christie M.R.; and Fuchtenbusch M.: Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB Study: detection of humoral immune response to islet antigens in early childhood. *Diabetes*, 45 (7): 967-73, 1996.
- Rott L.S.; Briskin M.J.; and Andrew D.P.: A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. *J.Immunol.*, 156(10): 3727-36, 1996.
- Reyssy L.; and Yki-Jarvinen H.: Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes mellitus. *Diabetes-Care*, 24(3): 549-54, 2001.
- Streeten D.H.P.; Gerstein M.M.; and Marmar B.M.: Reduced glucose tolerance in elderly human subjects. *Diabetes*, 14: 579-83, 1965.

- Slitzer H.S.; Allen E.W.; and Herron A.L.: Insulin secretion in response to glycemic stimulus: relations of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. *J.Clin.Invest.*, 46: 323-9, 1967.
- Standl E.; and Kolb H.J.: 2,3-Diphosphoglycerate fluctuations in erythrocytes reflecting pronounced blood glucose variations: In vivo and vitro studies in normal, diabetic and hypoglycemic subjects. *Diabetologia*, 9: 461-5, 1973.
- Saudek C.D.; Boulter P.R.; and Knopp R.H.: Sodium retention accompanying insulin treatment of diabetes mellitus. *Diabetes*, 23: 240-3, 1974.
- Schlichtkrull J.; Brange A.H.; and Christiansen O.: Monocomponent insulin and its clinical implication. In: *Radioimmunoassay methodology and applications in physiology and clinical studies*. *Horm.Metab.Res.*, (Suppl.1) 5: 134-38, 1974.
- Savage P.J.; Dippe S.E.; and Bennett P.H.: Hyper-insulinemia and hypo-insulinemia-insulin responses to oral carbohydrates over a wide spectrum of glucose tolerance. *Diabetes*, 24: 363-6, 1975.
- Schmid-Chonbein H.; and Volger E.: Red cell aggregation and red cell deformability in diabetes. *Diabetes*, 25 (Suppl.2): 897-900, 1976.
- Steffes M.W.; Brown D.M.; and Mauer S.M.: Bruch's membrane in experimentally induced diabetes mellitus in rats. *Clin.Res.*, 24: 584 A, 1976.
- Shenfield G.M.; Logan A.; and Shirling D.: Plasma insulin and glucose levels in maturity-onset diabetics treated with chlorpromide. *Diabetologia*, 13: 367-71, 1977.
- Stevens V.J.; Vlassara H.; and Alati A.: Non-enzymatic glycosylation of hemoglobin. *J.Biol.Chem.*, 252: 2998-3000, 1977.
- Shapiro R.; McManus M.; and Garrick L.: Non-enzymatic glycosylation of hemoglobin at multiple sites. *Metabolism*, 28: 427-29, 1979.
- Sartor G.; Schersten B.; and Carlstrom S.: ten-Year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. *Diabetes*, 29: 41-5, 1980.
- Srikanta S.; Rabizadeh A.; and Omar M.A.K.: Assay for islet cell antibodies: protein A monoclonal antibody method. *Diabetes*, 34: 300-305, 1980.
- Skillman T.A.; and Feldman J.M.: The pharmacology of sulfonylureas. *Am.J.Med.*, 70: 361-4, 1981.
- Skyler J.S.; and Cahil G.F.: Symposium on diabetes mellitus. Parts III. *Am.J.Med.*, 70: 101-214; 325-378; 579-630, 1981.

- Skyler J.S.; and Raptis S.: Symposium on Biosynthetic Human Insulin. *Diabetes Care*, 4: 139-264, 1981.
- Scarlett J.A.; Gray R.S.; and Griffin J.: Insulin treatment reverses the insulin resistant of type II diabetes mellitus. *Diabetes Care*, 5: 353-56, 1982.
- Schiffrin A.; and Belmonte M.M.: Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one year prospective study. *Diabetes*, 31: 255-59, 1982.
- Skyler J.S.: Symposium on Human Insulin of Recombinant DNA Origin. *Diabetes Care*, 5 (Suppl.2): 1-186, 1982.
- Skyler J.S.: Type II diabetes: toward improved understanding and rational therapy. *Diabetes Care*, 5: 447-52, 1982.
- Squifflet J.P.; Sutherland D.E.R.; and Rynasiewicz J.J.: Combined immunosuppressive therapy with cyclosporin A and azathioprine. A synergistic effect in three of four experimental models. *Transplantation*, 34: 315-19, 1982.
- Srikanta S.; Ganda O.P.; and Eiesenbarth G.S.: Islet cell antibodies and beta cell function in monozygotic triplets and twins initially discordant for type II diabetes mellitus. *N.Engl.J.Med.*, 308: 322-7, 1983.
- Srikanta S.; Ganda O.P.; and Jackson R.A.: Type I diabetes mellitus in monozygotic twines. Chronic progressive beta cell dysfunction. *Ann.Intern.Med.*, 99: 320-326, 1983.
- Strom T.B.; and Loertscher R.: Cyclosporine-induced nephrotoxicity. Inevitable and intractable. *N.Engl.J.Med.*, 311: 728-31, 1984.
- Soeldner J.S.; Inttleman S.; and Srikanta S.: Insulin-dependent diabetes and initiation of autoimmunity: Islet cell autoantibodies, insulin autoantibodies and beta cell function. *New.Engl.J.Med.*, 313: 893-900, 1985.
- Srikanta S.; Ganda O.P.; and Rabizadeh A.: First-degree relatives of patients with type I diabetes mellitus: Islet cell antibodies and abnormal insulin secretion. *New.Engl.J.Med.*, 313: 461-464, 1985.
- Simmons P.: Potential adhesion mechanisms for localization of haemopoietic progenitors to bone marrow stroma. *Leukemia Lymphoma*, 12: 353-7, 1994.
- Steiner M.; Reinhardt K.M.; and Krammer B.: Increased levels of soluble adhesion molecules in type II diabetes mellitus are independent in glycemic control. *Thromb.Haemost*, 72 (6): 979-84, 1994.
- Sano H.; Nakagawa N.; and Nakajima H.: Role of vascular cell adhesion molecule-1 and platelet-activating factor in selective eosinophil migration across

vascular endothelial cells. *Int. Arch. Allergy Immunol.*, 107(4): 533-40, 1995.

- Schmidt A.M.; Hori O.; and Chen J.X.: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. *J.Clin. Invest.*, 96 (3): 1395-1403, 1995.
- Schmidt A.M.; Crandall J.; and Hori O.: Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. *Br.J.Haematol.*, 92 (3): 747-50, 1996.
- Setty B.N.Y.; and Stuart M.J.: Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red cell adherence to endothelium: potential role in sickle cell disease. *Blood*, 88 (6): 2311-20, 1996.
- Sudhoff T.; Wehmeier A.; and Kliche K.O.: Levels of circulating endothelial adhesion molecules (sE-selectin and VCAM-1) in adult patients with acute leukemia. *Leukemia*, 10(4): 682-6, 1996.
- Sugihara S.; Konda S.; and Wataki K.: Clinical significance and time course of antibodies to glutamic acid decarboxylase in Japanese children with type I (insulin-dependent) diabetes mellitus. *Acta.Paediatr.*, 85 (5): 558-63, 1996.
- Savola K.; Bonifacio E.; and Sabbah E.: IA-2 antibodies a sensitive marker of IDDM with clinical onset in childhood and adolescence. *Diabetologia*, 41 (4): 424-9, 1998.
- Sherwin R.S.: Diabetes Mellitus. (From Cecil Textbook of Medicine. W.B.SAUNDERS COMPANY Philadelphia, Pennsylvania.21 first ed. edited by Lee Goldman, M.D. and Claude Bennett J., M.D.), p.: 1263-1377, 2000.
- Trivelli L.A.; Ranney H.M.; and Lai H.T.: Hemoglobin components in patients with diabetes mellitus. *N.Engl.J.Med.*, 284: 353-9, 1971.
- Tattersall R.B.; and Fajans S.S.: A difference between the inheritance of classic juvenile-onset and maturity-onset diabetes mellitus of young people. *Diabetes*, 24: 44-50, 1975.
- Timperly W.R.; Williams E.; and Ward J.D.: Abnormalities of small blood vessels in diabetic neuropathy. *Diabetologia*, 13: 437-41, 1977.
- Tanaka S.; Fujii S.; and Sek J.: Longitudinal study of chemical diabetes in an urban population in Japan. Genetic Enviromental Interaction in Diabetes Mellitus. (In: Melish J.S.; Hana J.; and Baba S., Ed.-Amsterdam). *Excerpta Medica*, pp.: 64-69, 1982.

- The Canadian Multicenter Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. *N.Engl.J.Med.*, 309: 809--15, 1983.
- Thivolet C.H.; and Tappaz M.: Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of type I (insulin-dependent) diabetes mellitus in high risk individuals. *Diabetologia*, 35: 570-576, 1992.
- Terry R.W.; Kwee L.; and Levine J.F.: Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein. *Proc.Natl.Acad.Sci. (USA)*, 90 (13): 5919-23, 1993.
- Tang S., Le-Ruppert K.C.; and Gabel V.P.: Expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on proliferating vascular endothelial cells in diabetic epiretinal membranes. *Br.J.Ophthalmol.*, 78 (5): 370-6, 1994.
- Tuomilehto J.; Zimmet P.; and Mackay I.R.: Antibodies to glutamic acid decarboxylase as predictors of insulin dependent diabetes mellitus before clinical onset of disease. *Lancet*, 343 (8910): 1383-5, 1994.
- Tsuruoka A.; Matsuda I.; and Toyota T.: Antibodies to GAD in Japanese diabetic patients: a multicenter study. *Diabetes Res.Clin.Pract.*, 28 (3): 191-9, 1995.
- Tschoepe D.: Adhesion molecules influencing atherosclerosis. *Diabetes Res.Clin.Pract.*, 30 Suppl.1: 19-24, 1996.
- Third Medical Department, Hospital Munchen-Schwabing, and Diabetes Research Institute, Munich, Germany. GAD IA-2-Combi determination as first-line screening for improved prediction of type I diabetes in relatives. *Diabetes*, 47 (4): 592-7, 1998.
- Triolo G.; Accardo A.; and Palumbo A.: IgG anti-endothelial cell antibodies (AECA) in type I diabetes mellitus; and induction of adhesion molecule expression in cultured endothelial cells. *Clin.Expir.Immunol.*, 111 (3): 491-6, 1998.
- Tietz N.W.: Diabetes Mellitus (From Tietz Textbook of Clinical Chemistry. W.B. SAUNDERS COMPANY Philadelphia, Pennsylvania.3rd ed. edited by Burtis, CA and Ashwood E.R.P.), pp.: 766-879, 1999.
- Torn C.; Landin-Olsson M.; and Ostman J.: Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds. *Diabetes-Metab-Res-Rev.*, 16(6): 442-7, 2000.

- Takino H.; Yamasaki H.; and Abiru N.: Antibodies to GAD in Japanese patients calssified as type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment. *Diabet-Med.*, 19(9): 730-4, 2002.
- Unger R.H.; and Madison L.L.: A new diagnostic procedure for mild diabetes mellitus. Evaluation of intravenous tolbutamide response test. *Diabetes*, 7: 455-9, 1958.
- Voor A.W.; Radhakrishnamurthy B.; and Srinivasan S.R.: Plasma glucose level related to blood pressure in 272 children, ages 7-15 years, sampled from a total biracial population. *Am.J.Epidemiol.*, 113: 347, 1981.
- Vigneri R.; Pezzino V.; Wong K.Y.; and Goldfine I.D.: Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to receptors in target cells. *J.Clin.Endocrinol.Metab.*, 54: 95-9, 1982.
- Vlassara H.: Chronic diabetic complications and tissue glycosylation. Relevant concern for diabetes-prone black population. *Diabetes Care*, 13 (11): 1180-5, 1990.
- Verfaillie P.: Role of bone matrix in normal and abnormal hematopoiesis. *Crit.Rev.Oncol.Hematol.*, 16: 210-5, 1994.
- Vandewalle C.L.; and Falorni A.: High Diagnostic Sensitivity of Glutamic Decarboxylase Autoantibodies in Insulin-Dependent Diabetes Mellitus with Clinical Onset Between Age 20 and 40 Years. *J.Clin.Endocrin. and Metab.*, Vol. 80, No.3: 846-851, 1995.
- Van Oosten M.; van-de-Bilt E.; and de-Vries H.E.: Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. *Hepatology*, 22(5): 1538-46, 1995.
- Vinik A.J.; Leichter S.B.; and Pittenger G.L.: Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. *Diabetes care*, 18 (9): 1225-32, 1995.
- Verg C.E.; Gianani R.; and Kawasaki E.: Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. *J.Autoimmun.*, 9 (3): 379-83, 1996 (Jun.).
- Verge C.E.; Gianani R.; and Kawasaki E.: Prediction of type I diabetes in first-degree relative using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. *Diabetes*, 45 (7): 926-33, 1996 (Jul.)
- Watanabe C.K.: Studies in the metabolic changes induced by administration of guanidine bases. I. Influence of injected guanidine hydrochloride upon blood sugar content. *J.Biol.Chem.*, 33: 253-56, 1918.

- White P.: Natural course and prognosis of juvenile diabetes. *Diabetes*, 5: 445-53, 1956.
- Ward J.D.; Fisher D.J.; and Barnes C.G.: Improvement in nerve conduction following treatment in newly diagnosed diabetes. *Lancet*, 1: 428-31, 1971.
- White P.; and Grahan C.A.: The child with diabetes. (In: Marble A.; White P.; Bradley R.F.; Krall L.P. Eds.; and Joslin's Diabetes Mellitus 11th ed. Philadelphia, Lea & Febiger), pp.: 339-360, 1971.
- West K.M.: Diet therapy of diabetes: An analysis of failure. *Ann.Intern.Med.*, 79: 425-29, 1973.
- West K.M.: Epidemiology of diabetes and its vascular lesions. (New York, Elsevier North-Holland, Inc.) pp.: 353-401, 1978.
- Westermarck P.; and Wilander E.: The influence of amyloid deposits on the islet cell volume in maturity-onset diabetes mellitus. *Diabetologia*, 15: 417-26, 1978.
- WHO Expert Committee on Diabetes Mellitus. (Second Report: Technical Report Series, No. 640, Geneva; World Health Organization) pp.: 31, 1980.
- WHO Expert Committee: Second Report on Diabetes Mellitus. (WHO Technical Report Series, No.646, Geneva; World Health Organization), pp.: 58 and pp. 31, 1980.
- Weir G.C.: Non-insulin-dependent diabetes mellitus: interplay between B-cell inadequacy and insulin resistance. *Am.J.Med.*, 73: 461-5, 1982.
- Wingard D.L.; Barrett-Connor E.; and Criqui H.: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. *Am.J.Epidemiol.*, 117: 19-23, 1983.
- Wagner O.F.; and Jilma B.: Putative role of adhesion molecules in metabolic disorders. *Hor.Metab.Res.*, 29 (12): 627-30, 1997.
- Yallow R.S.; and Berson S.A.: Immunoassay of endogenous plasma insulin in man. *J.Clin.Invest.*, 39: 1157-61, 1960.
- Yagihashi S.; Kudo K.; and Nishihira M.: Peripheral nerve structures of experimental diabetic rats and the effect of insulin treatment. *Tohoko J.Exp.Med.*, 127: 35-39, 1979.
- Yagihashi S.; and Matsunaga M.: Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy. *Tohoko J.Exp.Med.*, 129: 357-59, 1979.
- Yudkin J.S.; Alberti K.J.; and Meharty D.G.: Impaired glucose tolerance. *Br.Med.J.*, 301: 397-400, 1990.

- Yagi N.; Yokono K.; and Amano K.: Expression of intercellular adhesion molecule-1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. *Diabetes*, 44 (7): 744-52, 1995.
- Yokota I.; Matsuda J.; and Naito E.: Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. *Diabetes Care*, 21 (1): 49-52, 1998.
- Yoshizawa M.; Nagai Y.; and Ohsawa K.: Elevated serum levels of soluble vascular cell adhesion molecule-1 in NIDDM patients with proliferative diabetic retinopathy. *Diabetes Res.Clin.Pract.*, 42 (1): 65-70,1998.
- Zeytinoglu I.Y.; Gherondache C.M.; and Pincus G.: The process of aging: Serum glucose and immunoreactive insulin during the oral glucose tolerance test. *J.Am.Geriat.Soc.*, 17: 1-8, 1969.